AU2011327931B2 - Conjugates and their uses in molecular imaging - Google Patents

Conjugates and their uses in molecular imaging Download PDF

Info

Publication number
AU2011327931B2
AU2011327931B2 AU2011327931A AU2011327931A AU2011327931B2 AU 2011327931 B2 AU2011327931 B2 AU 2011327931B2 AU 2011327931 A AU2011327931 A AU 2011327931A AU 2011327931 A AU2011327931 A AU 2011327931A AU 2011327931 B2 AU2011327931 B2 AU 2011327931B2
Authority
AU
Australia
Prior art keywords
bifunctional
bifunctional compound
group
molecular imaging
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011327931A
Other languages
English (en)
Other versions
AU2011327931A1 (en
AU2011327931A2 (en
Inventor
James Russell Ballinger
David Berry
Philip John Blower
Yongmin Ma
Gregory Edgar David Mullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of AU2011327931A1 publication Critical patent/AU2011327931A1/en
Publication of AU2011327931A2 publication Critical patent/AU2011327931A2/en
Application granted granted Critical
Publication of AU2011327931B2 publication Critical patent/AU2011327931B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011327931A 2010-11-11 2011-11-11 Conjugates and their uses in molecular imaging Active AU2011327931B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1019118.7 2010-11-11
GB201019118A GB201019118D0 (en) 2010-11-11 2010-11-11 Conjugates and their uses in molecular imaging
PCT/GB2011/001599 WO2012063028A1 (en) 2010-11-11 2011-11-11 Conjugates and their uses in molecular imaging

Publications (3)

Publication Number Publication Date
AU2011327931A1 AU2011327931A1 (en) 2013-07-04
AU2011327931A2 AU2011327931A2 (en) 2013-07-11
AU2011327931B2 true AU2011327931B2 (en) 2017-02-23

Family

ID=43431334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011327931A Active AU2011327931B2 (en) 2010-11-11 2011-11-11 Conjugates and their uses in molecular imaging

Country Status (7)

Country Link
US (1) US9138495B2 (enExample)
EP (1) EP2637705B1 (enExample)
JP (1) JP5986095B2 (enExample)
AU (1) AU2011327931B2 (enExample)
ES (1) ES2625829T3 (enExample)
GB (1) GB201019118D0 (enExample)
WO (1) WO2012063028A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098442B2 (en) 2003-03-05 2006-08-29 Raytheon Company Thin micropolarizing filter, and a method for making it
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
EP4147724A1 (en) 2013-10-31 2023-03-15 Beth Israel Deaconess Medical Center Near-infrared fluorescent contrast bioimaging agents and methods of use thereof
US11001562B2 (en) 2013-10-31 2021-05-11 Beth Israel Deaconess Medical Center Near-infrared fluorescent nerve contrast agents and methods of use thereof
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
JP7253762B2 (ja) * 2017-12-27 2023-04-07 慈濟大學 タンパク質を表面に発現させた小胞によるオートファジー細胞およびアポトーシス細胞への薬剤送達
US20250082795A1 (en) 2023-09-12 2025-03-13 Curadel Surgical Innovations, Inc. Combinations of imaging agent conjugates and application thereof
CN120590625A (zh) * 2024-11-06 2025-09-05 江苏申命医疗科技有限公司 一种放射性核素标记的聚合物、其制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021947A1 (en) * 2007-08-13 2009-02-19 Ge Healthcare As Chelators, paramagnetic chelates thereof and their use as contrast agents in magnetic resonance imaging (mri)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AU2865995A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The 3-hydroxy-2(1h)-pyridinone chelating agents
WO2007042504A2 (fr) * 2005-10-07 2007-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8158804B2 (en) 2007-01-11 2012-04-17 Ge Healthcare As Chelating agents
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021947A1 (en) * 2007-08-13 2009-02-19 Ge Healthcare As Chelators, paramagnetic chelates thereof and their use as contrast agents in magnetic resonance imaging (mri)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERNANDES, S. S. et al., "Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium", Microbes and Infection. 2010, vol. 12, no. 4, pages 287-294 *
ZHOU, T. et al., "Iron Binding Dendrimers: A Novel Approach for the Treatment of Haemochromatosis", Journal of Medicinal Chemistry. 2006, vol. 49, pages 4171-4182 *

Also Published As

Publication number Publication date
WO2012063028A1 (en) 2012-05-18
GB201019118D0 (en) 2010-12-29
JP5986095B2 (ja) 2016-09-06
AU2011327931A1 (en) 2013-07-04
US9138495B2 (en) 2015-09-22
AU2011327931A2 (en) 2013-07-11
US20140056810A1 (en) 2014-02-27
EP2637705B1 (en) 2017-03-29
ES2625829T3 (es) 2017-07-20
EP2637705A1 (en) 2013-09-18
JP2014501714A (ja) 2014-01-23

Similar Documents

Publication Publication Date Title
AU2011327931B2 (en) Conjugates and their uses in molecular imaging
CA2822693C (en) Radiolabled her2 binding peptides
CN102438656B (zh) 预靶向试剂盒、方法和其中使用的试剂
Moreau et al. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes
Reissig et al. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin
Imberti et al. Enhancing PET signal at target tissue in vivo: dendritic and multimeric tris (hydroxypyridinone) conjugates for molecular imaging of αvβ3 integrin expression with gallium-68
CN103402550B (zh) 用含有18f的有机硅化合物标记的her2结合肽
CN119343151A (zh) 一种三功能化合物及其用途
US20150359913A1 (en) Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
US11633507B2 (en) HER2 binders
CA2998420A1 (en) Compositions for therapeutics, targeted pet imaging and methods of their use
Joaqui-Joaqui et al. Catechol-based functionalizable ligands for gallium-68 positron emission tomography imaging
Nakashima et al. Development of novel trifunctional chelating agents that enhance tumor retention of radioimmunoconjugates
Noor et al. Imaging somatostatin positive tumors with Tyr3-octreotate/octreotide conjugated to desferrioxamine B squaramide radiolabeled with either zirconium-89 or gallium-68
US9061080B2 (en) HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA
JP2024519603A (ja) 神経内分泌セラノスティクスのための前駆体および放射性トレーサー
KR102374087B1 (ko) 면역 컨쥬게이트 및 그의 용도
Ebenhan et al. Radiochemistry
Huynh The Evaluation of Radiometal Labeled Biomolecules for Imaging and Therapeutic Applications
WO2022156908A1 (en) Method for preparing a lyophilized composition
WO2022156907A1 (en) Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
JPH07285888A (ja) アルキレンジアミン四酢酸誘導体とその 放射能標識化合物
Nawaz A new gallium-68 labelled imaging agent for prostate cancer
Orvig et al. Trastuzumab-Conjugated Oxine-Based Ligand for [89zr] Zr4+ Immunopet
HK1193987A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 JUN 2013

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BALLINGER, JAMES RUSSELL; BERRY, DAVID; BLOWER, PHILIP JOHN; MA, YONGMIN AND MULLEN, GREGORY EDGAR DAVID

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BALLINGER, JAMES RUSSELL; BERRY, DAVID; BLOWER, PHILIP JOHN; MA, YONGMIN AND MULLEN, GREGORY EDGAR DAVID

FGA Letters patent sealed or granted (standard patent)